Recently, the DiaPlexQ™ STI6 Detection Kit (DiaPlexQ; Solgent Co., Ltd., Daejeon, South Korea), a European Conformity-In Vitro The PCR protocols and primers used are listed in Table S1 . After detection of PCR products by gel electrophoresis and purification, sequencing was performed on an automated ABI Prism 3730 instrument using a BigDye terminator cycle sequencing kit (Applied Biosystems, Foster City, CA, USA). Positive and negative controls were included in each run.
| MATERIAL S AND ME THODS
Analytical sensitivity was determined by directly comparing dilutions of six type strains in cell culture and in the DiaPlex assay. Serial dilutions of quantified target organism were made from 10 0 to 10 4 copies/reaction by spiking negative genital swabs/urine samples.
Serial dilutions were analyzed with 24 replicates per dilution. The lower detection limit was determined via Probit analysis. Analytical specificity of the DiaPlexQ assay was evaluated using 41 different microorganisms ( Table 1) .
| RE SULTS
At least one microorganism was detected in each of 877 specimens Among those, three samples had two discordant targets; thus, 78 discrepancies were produced. Fifty-nine results were DiaPlexQpositive and GeneFinder-negative. As shown in Table 3 , two were confirmed to be positive on monoplex PCR and sequencing.
Likewise, among 19 DiaPlexQ-negative and GeneFinder-positive results, one was confirmed to be positive by the monoplex PCR and sequencing.
The detection limits of the DiaPlexQ assay for CT and NG were one copy/reaction, whereas those for the other microorganisms (MH, TV, UU, and MG) were 10 copies/reaction. On the analytical specificity test, no false-positive results were obtained for any of the 41 microorganisms (Table 1) . have been introduced including strand displacement amplification, transcription-mediated amplification, and real-time PCR. 4, 15, 16 Some of these technologies will allow for rapid near-patient testing at the point of care and others have potential for high-throughput batch testing. The main limitation of this study was the lack of a reference standard and the retrospective nature of the study. We only resolved discrepancies for specimens with discordant results between the DiaPlexQ assay and the GeneFinder assay using monoplex PCR and sequencing. Therefore, we could not assess the diagnostic accuracy, including the sensitivity and specificity, of the real-time PCR assays.
| D ISCUSS I ON
Furthermore, we resolved the discordant results with conventional PCR and sequencing, which is generally less sensitive than real-time PCR. In addition, it was not possible to estimate the clinical incidence of the six STIs and positive/negative predictive values due to the retrospective nature of our study.
In conclusion, the DiaPlexQ assay produces results comparable to those of the GeneFinder assay. The DiaPlexQ assay will be a useful tool for STD pathogen detection in clinical laboratories.
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